Spots Global Cancer Trial Database for oligodendroglioma
Every month we try and update this database with for oligodendroglioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Proteomic Characterization of Aggressive Oligodendrogliomas | NCT04843085 | Oligodendroglio... | Proteomic analy... | - | Hospices Civils de Lyon | |
| Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes | NCT04304300 | Astrocytoma, Gr... Astrocytoma, Gr... Oligodendroglio... Oligodendroglio... | 18 Years - | Erasmus Medical Center | ||
| 5-ALA in Recurrent Glioma | NCT02119338 | Glioma | 5-ala | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | NCT00080054 | Glioma Glioblastoma Astrocytoma Oligodendroglio... Brain Neoplasm | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved | NCT02530320 | Oligodendroglio... Oligoastrocytom... | Palbociclib | 18 Years - | Grupo Español de Investigación en Neurooncología | |
| Fatigue, Sleep and Cytokines in Primary Brain Tumor (PBT) Patients | NCT00876499 | Brain Cancer | Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Safety Study of Afatinib for Brain Cancer | NCT02423525 | Brain Cancer | Afatinib | 18 Years - | Saint John's Cancer Institute | |
| Natural History of Patients With Brain and Spinal Cord Tumors | NCT00009035 | Astrocytoma Oligodendroglio... Glioblastoma Glioma Anaplastic Glio... | 1 Year - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations | NCT05267106 | Glioblastoma Adult-type Diff... | Pemigatinib | 18 Years - 99 Years | Incyte Corporation | |
| Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | NCT03220646 | Brain Tumor | abemaciclib abemaciclib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Genetic Analysis of Brain Tumors | NCT00031538 | Glioma Glioblastoma Mu... Anaplastic Astr... Oligodendroglio... Astrocytoma | 1 Year - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | NCT03649464 | Glioblastoma Astrocytoma Oligodendroglio... | OKN-007 | 18 Years - | Oblato, Inc. | |
| SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | NCT04923126 | Low-Grade Gliom... Recurrent Low-G... Progressive Low... | Mirdametinib | 2 Years - 24 Years | St. Jude Children's Research Hospital | |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | NCT01609790 | Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Recurrent Brain... Recurrent Gliob... | Bevacizumab Laboratory Biom... Pharmacological... Placebo Adminis... Trebananib | 18 Years - | National Cancer Institute (NCI) | |
| Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols | NCT00035373 | Glioblatoma Gliosarcoma Anaplastic Astr... Oligodendroglio... Anaplastic Olig... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma | NCT05561374 | High-grade Glio... Oligodendroglio... Astrocytoma Glioblastoma Mu... | Low-dose OKN-00... Low-dose OKN-00... Mid-dose OKN-00... High-dose OKN-0... | 18 Years - | Oblato, Inc. | |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | NCT03014804 | Giant Cell Glio... Gliosarcoma Oligodendroglio... Recurrent Gliob... Small Cell Glio... | autologous dend... Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A... | 18 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning | NCT05624736 | Astrocytoma Glioblastoma Mu... Oligodendroglio... | multi-parametri... Pathology exami... | 18 Years - 90 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma | NCT01649830 | Astrocytoma Oligodendroglio... Oligodendroastr... | Radiotherapy Temozolomide | 18 Years - 60 Years | Sun Yat-sen University | |
| Dexanabinol in Patients With Brain Cancer | NCT01654497 | Brain Cancer | Dexanabinol | 18 Years - | University of California, San Diego | |
| Vorasidenib Expanded Access Program | NCT05592743 | Glioma Recurrence Disease Attribu... Pathologic Proc... Neoplasms, Neur... Neuroectodermal... Neoplasms, Germ... Neoplasms by Hi... Neoplasms Neoplasms, Glan... Neoplasms, Nerv... | Vorasidenib | 12 Years - | Servier | |
| A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | NCT02924038 | Glioma Malignant Gliom... Astrocytoma, Gr... Oligodendroglio... Glioma, Astrocy... Oligoastrocytom... | IMA950 poly-ICLC Varlilumab | 18 Years - | University of California, San Francisco | |
| Safety Study of Afatinib for Brain Cancer | NCT02423525 | Brain Cancer | Afatinib | 18 Years - | Saint John's Cancer Institute | |
| Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | NCT03649464 | Glioblastoma Astrocytoma Oligodendroglio... | OKN-007 | 18 Years - | Oblato, Inc. | |
| FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma | NCT01089244 | Astrocytoma Oligoastrocytom... Oligodendroglio... | 18 Years - | Ludwig-Maximilians - University of Munich | ||
| Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors | NCT02372409 | Glioma Pilocytic Astro... Anaplastic Astr... Glioblastoma Mixed Oligoastr... Mixed Glioma Oligodendroglio... Optic Glioma Astrocytoma | MRI-guided lase... Doxorubicin Etoposide Dynamic contras... Dynamic suscept... | 3 Years - 21 Years | Washington University School of Medicine | |
| A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma | NCT00683761 | Malignant Gliom... Glioblastoma Mu... GBM Astrocytoma Oligodendroglio... | 131I-TM601 | 18 Years - | TransMolecular | |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | NCT04541082 | Central Nervous... Glioblastoma Gliosarcoma, Ad... Anaplastic Olig... Anaplastic Astr... Pilocytic Astro... Oligodendroglio... Gliomatosis Cer... Pleomorphic Xan... Anaplastic Pleo... Diffuse Midline... Ependymoma Ependymoma, Ana... Medulloblastoma Teratoid Rhabdo... Neuroectodermal... Neuroectodermal... Anaplastic Meni... Atypical Mening... Choroid Plexus ... Pineal Tumor Diffuse Astrocy... Glial Tumor | ONC206 | 18 Years - | Chimerix | |
| Investigational Imaging Technique During Brain Surgery | NCT05513859 | Astrocytoma Glioblastoma Oligodendroglio... | Craniotomy Quantitative Ob... | 18 Years - | Emory University | |
| Investigational Imaging Technique During Brain Surgery | NCT05513859 | Astrocytoma Glioblastoma Oligodendroglio... | Craniotomy Quantitative Ob... | 18 Years - | Emory University | |
| A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas | NCT02209428 | Astrocytoma Oligodendroglio... Oligoastrocytom... | Temozolomide | 18 Years - 40 Years | Huashan Hospital | |
| A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | NCT02924038 | Glioma Malignant Gliom... Astrocytoma, Gr... Oligodendroglio... Glioma, Astrocy... Oligoastrocytom... | IMA950 poly-ICLC Varlilumab | 18 Years - | University of California, San Francisco | |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations | NCT05267106 | Glioblastoma Adult-type Diff... | Pemigatinib | 18 Years - 99 Years | Incyte Corporation | |
| 5-ALA in Recurrent Glioma | NCT02119338 | Glioma | 5-ala | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | NCT03014804 | Giant Cell Glio... Gliosarcoma Oligodendroglio... Recurrent Gliob... Small Cell Glio... | autologous dend... Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A... | 18 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | NCT00392171 | Glioma Astrocytoma Oligodendroglio... Glioblastoma | Temozolomide | 19 Years - 70 Years | Merck Sharp & Dohme LLC | |
| FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma | NCT01089244 | Astrocytoma Oligoastrocytom... Oligodendroglio... | 18 Years - | Ludwig-Maximilians - University of Munich | ||
| A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | NCT02381886 | Advanced Malign... | IDH305 | 18 Years - | Novartis | |
| Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO) | NCT06038760 | Brain Tumor Glioma, Maligna... Ependymoma Oligodendroglio... Glioblastoma | Resection | 18 Years - | Ourotech, Inc. | |
| A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain | NCT01403311 | Glioma | 5-Aminolevuline... | 18 Years - | Legacy Health System | |
| A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma | NCT00389090 | Glioma Astrocytoma Oligodendroglio... Oligoastrocytom... | Temozolomide an... | 18 Years - | Keryx / AOI Pharmaceuticals, Inc. | |
| Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology | NCT04648462 | Astrocytoma Ependymoma Ganglioglioma Oligodendroglio... Optic Nerve Gli... Meningioma Nerve Sheath Ne... Adenoma Craniopharyngio... Hemangiopericyt... Germinoma Neurilemmoma | ProTRAIT | 18 Years - | Maastricht Radiation Oncology | |
| A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | NCT02924038 | Glioma Malignant Gliom... Astrocytoma, Gr... Oligodendroglio... Glioma, Astrocy... Oligoastrocytom... | IMA950 poly-ICLC Varlilumab | 18 Years - | University of California, San Francisco | |
| Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas | NCT06241391 | Glioma Astrocytoma Anaplastic Astr... Oligodendroglio... Glioblastoma Mu... | PSMA PET-CT | 18 Years - | All India Institute of Medical Sciences, Bhubaneswar | |
| The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) | NCT03896958 | Cancer, All Typ... Cancer of Liver Cancer of Stoma... Cancer of Head ... Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Colon Cancer Skin Cancer of Cervi... Cancer, Metasta... Cancer of Laryn... Cancer of Neck Cancer of Lung Cancer of Brain... Cancer of Vulva... Cancer of Pancr... Sarcoma GIST Small-cell Lung... Adenocarcinoma ... Cancer of Prost... Cancer, Advance... Adrenal Cancer Testicular Canc... Uterine Cancer Bronchoalveolar... Cancer Unknown ... Glioblastoma Mu... Oligodendroglio... Breast Cancer Renal Cell Carc... Hepatocellular ... Cholangiocarcin... Squamous Cell C... Transitional Ce... Cancer, Other Cancer, Anal Melanoma Cancer, Bile Du... Cancer, Bladder Cancer Cords Vo... Cancers Cell Ne... Cancer Differen... Cancer, Anaplas... | 1 Month - 99 Years | SpeciCare | ||
| Antineoplaston Therapy in Treating Children With Brain Tumors | NCT00003458 | Childhood Brain... | Antineoplaston ... | 6 Months - 18 Years | Burzynski Research Institute | |
| Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases | NCT03796273 | Anatomic Stage ... Astrocytoma Breast Carcinom... Glioma Invasive Breast... Oligodendroglio... Prognostic Stag... Recurrent Gliom... | Best Practice Ketoconazole | 18 Years - | Wake Forest University Health Sciences | |
| NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma | NCT03353896 | Anaplastic Olig... Oligoastrocytom... Oligodendroglio... | Wear novoTTF-20... Quality-of-Life... | 19 Years - | University of Southern California | |
| Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma | NCT05512351 | Oligodendroglio... | Tislelizumab pl... | 18 Years - | Henan Provincial People's Hospital | |
| HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | NCT02457845 | Supratentorial ... Malignant Gliom... Glioblastoma Anaplastic Astr... PNET Cerebral Primit... Embryonal Tumor | G207 | 3 Years - 18 Years | University of Alabama at Birmingham | |
| The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) | NCT03896958 | Cancer, All Typ... Cancer of Liver Cancer of Stoma... Cancer of Head ... Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Colon Cancer Skin Cancer of Cervi... Cancer, Metasta... Cancer of Laryn... Cancer of Neck Cancer of Lung Cancer of Brain... Cancer of Vulva... Cancer of Pancr... Sarcoma GIST Small-cell Lung... Adenocarcinoma ... Cancer of Prost... Cancer, Advance... Adrenal Cancer Testicular Canc... Uterine Cancer Bronchoalveolar... Cancer Unknown ... Glioblastoma Mu... Oligodendroglio... Breast Cancer Renal Cell Carc... Hepatocellular ... Cholangiocarcin... Squamous Cell C... Transitional Ce... Cancer, Other Cancer, Anal Melanoma Cancer, Bile Du... Cancer, Bladder Cancer Cords Vo... Cancers Cell Ne... Cancer Differen... Cancer, Anaplas... | 1 Month - 99 Years | SpeciCare | ||
| PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas | NCT05190172 | Oligodendroglio... Oligodendroglio... Diffuse Astrocy... | Radiation thera... | 18 Years - 65 Years | Oslo University Hospital | |
| Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas | NCT01966809 | Brain Tumor, Re... | Photofrin photo... | 18 Years - | Medical College of Wisconsin | |
| HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas | NCT00874861 | Astrocytoma Oligoastrocytom... Oligodendroglio... | Peptide vaccine... | 18 Years - | University of Pittsburgh | |
| Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies | NCT04047264 | Anaplastic Astr... Anaplastic Olig... Diffuse Astrocy... Diffuse Glioma Glioblastoma Metastatic Mali... Oligodendroglio... | Microdialysis | 18 Years - | Mayo Clinic | |
| Social Determinants of Health in Glioblastoma Population | NCT03900689 | Glioma Astrocytoma Oligodendroglio... Ependymoma Ganglioglioma Pleomorphic Xan... | Part 1 Survey G... Part 2 Focus Gr... | 18 Years - | Wake Forest University Health Sciences | |
| Prolonged Daily Temozolomide for Low-Grade Glioma | NCT00165360 | Glioma Astrocytoma Oligodendroglio... | Temozolomide | 18 Years - | Dana-Farber Cancer Institute | |
| All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | NCT05345002 | Glioma IDH Mutation Astrocytoma Oligodendroglio... | Retifanlimab All-trans retin... | 18 Years - | University of Pennsylvania | |
| NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma | NCT03353896 | Anaplastic Olig... Oligoastrocytom... Oligodendroglio... | Wear novoTTF-20... Quality-of-Life... | 19 Years - | University of Southern California | |
| Natural History of Patients With Brain and Spinal Cord Tumors | NCT00009035 | Astrocytoma Oligodendroglio... Glioblastoma Glioma Anaplastic Glio... | 1 Year - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | NCT01836549 | Anaplastic Astr... Anaplastic Epen... Astrocytoma, Gr... Ependymoma Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Brainstem Tumor... | imetelstat sodi... | 12 Months - 21 Years | Pediatric Brain Tumor Consortium | |
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | NCT05956821 | Glioblastoma Mu... Anaplastic Astr... Fibrillary Astr... Oligodendroglio... Diffuse Intrins... Diffuse Intrins... DIPG Brain Tumo... H3 K27M | SIACI of cetuxi... | 1 Year - 21 Years | University of Miami | |
| Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | NCT01836549 | Anaplastic Astr... Anaplastic Epen... Astrocytoma, Gr... Ependymoma Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Brainstem Tumor... | imetelstat sodi... | 12 Months - 21 Years | Pediatric Brain Tumor Consortium | |
| Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas | NCT05393258 | Astrocytoma Oligodendroglio... Glioma, Maligna... | temporally-modu... | 18 Years - | Washington University School of Medicine | |
| Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors | NCT01682746 | Brain Tumor, Re... | Photofrin (porf... | 6 Months - 18 Years | Medical College of Wisconsin | |
| Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | NCT04623931 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Diffuse Astrocy... Glioblastoma Oligoastrocytom... Oligodendroglio... WHO Grade II Gl... WHO Grade III G... | Quality-of-Life... Questionnaire A... Radiation Thera... Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| First in Patient Study for PF-06840003 in Malignant Gliomas | NCT02764151 | Oligodendroglio... Astrocytoma Malignant Gliom... | PF-06840003 | 18 Years - | Pfizer | |
| Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma | NCT02549833 | Oligodendroglio... Astrocytoma, Gr... Glioma, Astrocy... Glioma Malignant Gliom... Oligoastrocytom... | GBM6-AD and pol... GBM6-AD and pol... | 18 Years - | University of California, San Francisco | |
| Genetic Analysis of Brain Tumors | NCT00031538 | Glioma Glioblastoma Mu... Anaplastic Astr... Oligodendroglio... Astrocytoma | 1 Year - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors | NCT01682746 | Brain Tumor, Re... | Photofrin (porf... | 6 Months - 18 Years | Medical College of Wisconsin | |
| Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma | NCT00591058 | Malignant Gliom... Glioblastoma Mu... GBM Astrocytoma Oligodendroglio... | TM-601 | 18 Years - | TransMolecular | |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | NCT01609790 | Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Recurrent Brain... Recurrent Gliob... | Bevacizumab Laboratory Biom... Pharmacological... Placebo Adminis... Trebananib | 18 Years - | National Cancer Institute (NCI) | |
| Vorasidenib Expanded Access Program | NCT05592743 | Glioma Recurrence Disease Attribu... Pathologic Proc... Neoplasms, Neur... Neuroectodermal... Neoplasms, Germ... Neoplasms by Hi... Neoplasms Neoplasms, Glan... Neoplasms, Nerv... | Vorasidenib | 12 Years - | Servier | |
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | NCT05956821 | Glioblastoma Mu... Anaplastic Astr... Fibrillary Astr... Oligodendroglio... Diffuse Intrins... Diffuse Intrins... DIPG Brain Tumo... H3 K27M | SIACI of cetuxi... | 1 Year - 21 Years | University of Miami | |
| Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models | NCT04970615 | Brain Tumor Glioma Glioblastoma Astrocytoma Neoplasm, Brain Oligodendroglio... Patient Educati... Decision Making... | Three-dimension... | 18 Years - 100 Years | Radboud University Medical Center | |
| Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors | NCT01682746 | Brain Tumor, Re... | Photofrin (porf... | 6 Months - 18 Years | Medical College of Wisconsin | |
| Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma | NCT00591058 | Malignant Gliom... Glioblastoma Mu... GBM Astrocytoma Oligodendroglio... | TM-601 | 18 Years - | TransMolecular | |
| A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | NCT02381886 | Advanced Malign... | IDH305 | 18 Years - | Novartis | |
| A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). | NCT05331521 | Oligodendroglio... | CETEG PCV RT | 18 Years - | University Hospital Heidelberg | |
| Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas | NCT00360828 | Astrocytoma Glioma Oligodendroglio... | Irinotecan Hydr... Continued Irino... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
